ARCHIVED - Galicia already manufacturing Novavax in anticipation of April approval
The manufacturing plant in O Porriño (Pontevedra) is also working in cooperation with the CSIC (Spanish National Research Council) to develop new vaccines, on which trials have yet to begin.
The vaccination against COVID-19 by Novavax, which will be manufactured for European distribution at the Biofabri plant in O Porriño, Pontevedra (Galicia), may be authorised in April, the Spanish Health Minister has reported.
The EMA (European Medicine Agency) will be studying the vaccine by the American development company once it has concluded its deliberations about the Janssen vaccine, which it is examining now.
The vaccine has so far been showing very good results in clinical trials, even where new variants such as the South African strain are concerned and it is hoped that the vaccine may be approved for use by April.
Biofabri (Zendal) is the first Spanish company to manufacture a complete COVID-19 vaccine, and the Spanish government is confident that it will place Spain in a strong position at a European and international level, as well as to boost the supplies available, Health Minister Carolina Darias told the press.
The EU has ordered 200 million doses of Novavax, which will be manufactured at the installations in Galicia and two other European locations, before being sent to Novavax for packaging and distribution.
Image: Health Minister Carolina Darias visiting the plant this week.